New drug cocktail aims to beat leukemia in patients too frail for standard chemo

NCT ID NCT07172204

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing a combination of two drug regimens—VA (venetoclax and azacitidine) and low-dose CHA (cladribine, homoharringtonine, and cytarabine)—given in alternating cycles to newly diagnosed acute myeloid leukemia (AML) patients aged 60 or older who cannot tolerate intensive chemotherapy. The goal is to see if this approach can clear leukemia cells from the bone marrow (MRD negativity) and improve outcomes. The study will enroll 25 participants across multiple centers in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax, azacitidine, cladribine, homoharringtonine, and cytarabine
What this could lead to: If successful, this could offer a more effective treatment option for older or frail AML patients who cannot tolerate standard chemotherapy, potentially leading to better disease control and longer remission.
What could go wrong: This is a small, early-phase (phase II) study with only 25 participants, so results may not apply to all patients. The drug combination also carries risks like infection, bleeding, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE 60 AND OLDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE 60 AND OLDER AGE ≥60 INTENSIVE CHEMOTHERAPY UNFIT NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Beijing Chao-Yang Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, China
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
Shenzhen University General Hospital
RECRUITING

Shenzhen, Guangdong, China
the First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, China
the Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.